Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD.

Autor:	Etra A; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., El Jurdi N; Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN., Katsivelos N; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Kwon D; Department of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Gergoudis S; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Morales G; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Spyrou N; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Kowalyk S; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Aguayo-Hiraldo P; Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA., Akahoshi Y; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Ayuk F; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Baez J; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Betts BC; Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN., Chanswangphuwana C; Blood and Marrow Transplantation Program, Chulalongkorn University, Bangkok, Thailand., Chen YB; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA., Choe H; Division of Hematology, James Cancer Center, The Ohio State University, Columbus, OH., DeFilipp Z; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA., Gleich S; Department of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany., Hexner E; Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA., Hogan WJ; Division of Hematology, Mayo Clinic, Rochester, MN., Holler E; Department of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany., Kitko CL; Pediatric Stem Cell Transplant Program, Vanderbilt University Medical Center, Nashville, TN., Kraus S; Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany., Al Malki M; Hematology/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA., MacMillan M; Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN., Pawarode A; Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI., Quagliarella F; Ospedale Bambino Gesu', Rome, Italy., Qayed M; Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA., Reshef R; Blood and Marrow Transplantation Program, Columbia University Medical Center, New York, NY., Schechter T; Division of Hematology/Oncology/BMT, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada., Vasova I; Med. Klinik III/Poliklinik, Universitatsklinik Erlangen, Erlangen, Germany., Weisdorf D; Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN., Wölfl M; Pediatric Blood and Marrow Transplantation Program, Children's Hospital, University of Würzburg, Würzburg, Germany., Young R; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Nakamura R; Hematology/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA., Ferrara JLM; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Levine JE; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Holtan S; Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2024 Jun 25; Vol. 8 (12), pp. 3284-3292.
DOI:	10.1182/bloodadvances.2023011049
Abstrakt:	Abstract: Graft-versus-host disease (GVHD) is a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Algorithms containing either the gastrointestinal (GI) GVHD biomarker amphiregulin (AREG) or a combination of 2 GI GVHD biomarkers (suppressor of tumorigenicity-2 [ST2] + regenerating family member 3 alpha [REG3α]) when measured at GVHD diagnosis are validated predictors of NRM risk but have never been assessed in the same patients using identical statistical methods. We measured the serum concentrations of ST2, REG3α, and AREG by enzyme-linked immunosorbent assay at the time of GVHD diagnosis in 715 patients divided by the date of transplantation into training (2004-2015) and validation (2015-2017) cohorts. The training cohort (n = 341) was used to develop algorithms for predicting the probability of 12-month NRM that contained all possible combinations of 1 to 3 biomarkers and a threshold corresponding to the concordance probability was used to stratify patients for the risk of NRM. Algorithms were compared with each other based on several metrics, including the area under the receiver operating characteristics curve, proportion of patients correctly classified, sensitivity, and specificity using only the validation cohort (n = 374). All algorithms were strong discriminators of 12-month NRM, whether or not patients were systemically treated (n = 321). An algorithm containing only ST2 + REG3α had the highest area under the receiver operating characteristics curve (0.757), correctly classified the most patients (75%), and more accurately risk-stratified those who developed Minnesota standard-risk GVHD and for patients who received posttransplant cyclophosphamide-based prophylaxis. An algorithm containing only AREG more accurately risk-stratified patients with Minnesota high-risk GVHD. Combining ST2, REG3α, and AREG into a single algorithm did not improve performance. (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu